Inclisiran safety and efficacy in real-world clinical practice: results of a retrospective observational investigation - PubMed
5 hours ago
- #hypercholesterolemia
- #PCSK9i
- #LDL-C
- Inclisiran significantly reduces LDL-C levels by 59.5% with statin ± ezetimibe and 56% without.
- Higher likelihood of achieving LDL-C <55 mg/dl when inclisiran is used with statins ± ezetimibe.
- Adverse effects were mild, occurring in 5.8% of patients.
- Study confirms inclisiran as a well-tolerated and potent LDL-C-lowering treatment.
- Greater efficacy observed when inclisiran is combined with statins ± ezetimibe.